Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors

Cancer Cell

Volumn 32, Issue 5, 2017, Pages 654-668.e5

  Kumar, Vinit ^a   Donthireddy, Laxminarasimha ^a   Marvel, Douglas ^a   Condamine, Thomas ^a   Wang, Fang ^a   Lavilla Alonso, Sergio ^a   Hashimoto, Ayumi ^a   Vonteddu, Prashanthi ^a   Behera, Reeti ^a   Goins, Marlee A ^e   Mulligan, Charles ^e   Nam, Brian ^e   Hockstein, Neil ^e   Denstman, Fred ^e   Shakamuri, Shanti ^e   Speicher, David W ^a   Weeraratna, Ashani T ^a   Chao, Timothy ^c   Vonderheide, Robert H ^c   Languino, Lucia R ^g   Ordentlich, Peter ^b   Liu, Qin ^a   Xu, Xiaowei ^c   Lo, Albert ^d   Puré, Ellen ^d   Zhang, Chunsheng ^h   Loboda, Andrey ^h   Sepulveda, Manuel A ^f   Snyder, Linda A ^f   Gabrilovich, Dmitry I ^a   more..

^a WISTAR INSTITUTE   (United States)

^b Syndax Pharmaceuticals Inc ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^e HELEN F GRAHAM CANCER CENTER   (United States)

^f Janssen Pharmaceuticals R D LLC   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CSF1R; fibroblasts; granulocytes; M CSF; macrophages; PMN MDSC

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR 1 RECEPTOR INHIBITOR; COLONY STIMULATING FACTOR RECEPTOR; HISTONE DEACETYLASE 2; JNJ 40346527; NEUTRALIZING ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; 1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; CARBANILAMIDE DERIVATIVE; HDAC2 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; JNJ-40346527; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER INHIBITION; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FEMALE; GENE EXPRESSION; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; MACROPHAGE; METABOLISM; MONOCYTE; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CANCER-ASSOCIATED FIBROBLASTS; CELL LINE, TUMOR; GRANULOCYTES; HISTONE DEACETYLASE 2; HUMANS; IMIDAZOLES; MACROPHAGES; MICE, INBRED C57BL; MONOCYTES; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS, EXPERIMENTAL; PHENYLUREA COMPOUNDS; PYRIDINES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTORS, INTERLEUKIN-8B; TUMOR BURDEN;

EID: 85033725863     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.10.005     Document Type: Article

References (61)

1. Butowski, N., Colman, H., De Groot, J.F., Omuro, A.M., Nayak, L., Wen, P.Y., Cloughesy, T.F., Marimuthu, A., Haidar, S., Perry, A., et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 18 (2016), 557–564.
2. Carus, A., Ladekarl, M., Hager, H., Pilegaard, H., Nielsen, P.S., Donskov, F., Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. Lung Cancer 81 (2013), 130–137.
3. Challacombe, J.M., Suhrbier, A., Parsons, P.G., Jones, B., Hampson, P., Kavanagh, D., Rainger, G.E., Morris, M., Lord, J.M., Le, T.T., et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J. Immunol. 177 (2006), 8123–8132.
4. Chao, T., Furth, E.E., Vonderheide, R.H., CXCR2-dependent accumulation of tumor-associated neutrophils regulates t-cell immunity in pancreatic ductal adenocarcinoma. Cancer Immunol. Res. 4 (2016), 968–982.
5. Condamine, T., Dominguez, G., Youn, J., Kossenkov, A., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. Lectin-type oxidized LDL receptor 1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci. Immunol., 1, 2016, 10.1126/sciimmunol.aaf8943.
6. Conway, J.G., McDonald, B., Parham, J., Keith, B., Rusnak, D.W., Shaw, E., Jansen, M., Lin, P., Payne, A., Crosby, R.M., et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc. Natl. Acad. Sci. USA 102 (2005), 16078–16083.
7. Coussens, L.M., Pollard, J.W., Leukocytes in mammary development and cancer. Cold Spring Harb. Perspect. Biol., 3, 2011, 10.1101/cshperspect.a003285.
8. DeNardo, D.G., Brennan, D.J., Rexhepaj, E., Ruffell, B., Shiao, S.L., Madden, S.F., Gallagher, W.M., Wadhwani, N., Keil, S.D., Junaid, S.A., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1 (2011), 54–67.
9. Fearon, D.T., The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol. Res. 2 (2014), 187–193.
10. Feig, C., Jones, J.O., Kraman, M., Wells, R.J., Deonarine, A., Chan, D.S., Connell, C.M., Roberts, E.W., Zhao, Q., Caballero, O.L., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 110 (2013), 20212–20217.
11. Finke, J., Ko, J., Rini, B., Rayman, P., Ireland, J., Cohen, P., MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 11 (2011), 856–861.
12. Gabrilovich, D.I., Myeloid-derived suppressor cells. Cancer Immunol. Res. 5 (2017), 3–8.
13. Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12 (2012), 253–268.
14. Gascard, P., Tlsty, T.D., Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 30 (2016), 1002–1019.
15. Genovese, M.C., Hsia, E., Belkowski, S.M., Chien, C., Masterson, T., Thurmond, R.L., Manthey, C.L., Yan, X.D., Ge, T., Franks, C., Greenspan, A., Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy. J. Rheumatol. 42 (2015), 1752–1760.
16. Gentles, A.J., Newman, A.M., Liu, C.L., Bratman, S.V., Feng, W., Kim, D., Nair, V.S., Xu, Y., Khuong, A., Hoang, C.D., et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21 (2015), 938–945.
17. Greenberg, N.M., DeMayo, F., Finegold, M.J., Medina, D., Tilley, W.D., Aspinall, J.O., Cunha, G.R., Donjacour, A.A., Matusik, R.J., Rosen, J.M., Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92 (1995), 3439–3443.
18. Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
19. Guleria, I., Pollard, J.W., Aberrant macrophage and neutrophil population dynamics and impaired Th1 response to Listeria monocytogenes in colony-stimulating factor 1-deficient mice. Infect. Immun. 69 (2001), 1795–1807.
20. Huang, T.S., Shyu, Y.C., Chen, H.Y., Yuan, S.S., Shih, J.N., Chen, P.J., A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma. J. Viral Hepat. 20 (2013), 729–743.
21. Kato, M., Takahashi, M., Akhand, A.A., Liu, W., Dai, Y., Shimizu, S., Iwamoto, T., Suzuki, H., Nakashima, I., Transgenic mouse model for skin malignant melanoma. Oncogene 17 (1998), 1885–1888.
22. Kumar, V., Cheng, P., Condamine, T., Mony, S., Languino, L.R., McCaffrey, J.C., Hockstein, N., Guarino, M., Masters, G., Penman, E., et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 44 (2016), 303–315.
23. Ladanyi, A., Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res. 28 (2015), 490–500.
24. Lin, E.Y., Nguyen, A.V., Russell, R.G., Pollard, J.W., Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193 (2001), 727–740.
25. Lo, A., Wang, L.C., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R.A., Bajor, D.J., Clendenin, C., et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 75 (2015), 2800–2810.
26. Lokeshwar, B.L., Lin, H.S., Development and characterization of monoclonal antibodies to murine macrophage colony-stimulating factor. J. Immunol. 141 (1988), 483–488.
27. Lucas, T., Abraham, D., Aharinejad, S., Modulation of tumor associated macrophages in solid tumors. Front. Biosci. 13 (2008), 5580–5588.
28. MacDonald, K.P., Palmer, J.S., Cronau, S., Seppanen, E., Olver, S., Raffelt, N.C., Kuns, R., Pettit, A.R., Clouston, A., Wainwright, B., et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116 (2010), 3955–3963.
29. Mao, Z.Y., Zhu, G.Q., Xiong, M., Ren, L., Bai, L., Prognostic value of neutrophil distribution in cholangiocarcinoma. World J. Gastroenterol. 21 (2015), 4961–4968.
30. Messmer, M.N., Netherby, C.S., Banik, D., Abrams, S.I., Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol. Immunother. 64 (2015), 1–13.
31. Meyer, C., Cagnon, L., Costa-Nunes, C.M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., Speiser, D.E., Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63 (2014), 247–257.
32. Mishra, P., Banerjee, D., Ben-Baruch, A., Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J. Leukoc. Biol. 89 (2011), 31–39.
33. Mitchem, J.B., Brennan, D.J., Knolhoff, B.L., Belt, B.A., Zhu, Y., Sanford, D.E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73 (2013), 1128–1141.
34. Mok, S., Koya, R.C., Tsui, C., Xu, J., Robert, L., Wu, L., Graeber, T.G., West, B.L., Bollag, G., Ribas, A., Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 74 (2014), 153–161.
35. Mok, S., Tsoi, J., Koya, R.C., Hu-Lieskovan, S., West, B.L., Bollag, G., Graeber, T.G., Ribas, A., Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer, 15, 2015, 356.
36. Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., Alizadeh, A.A., Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12 (2015), 453–457.
37. Noman, M.Z., Janji, B., Hu, S., Wu, J.C., Martelli, F., Bronte, V., Chouaib, S., Tumor-promoting effects of myeloid-derived suppressor cells are potentiated by hypoxia-induced expression of miR-210. Cancer Res. 75 (2015), 3771–3787.
38. Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R.P., Kalinski, P., PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71 (2011), 7463–7470.
39. Ohno, H., Kubo, K., Murooka, H., Kobayashi, Y., Nishitoba, T., Shibuya, M., Yoneda, T., Isoe, T., A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol. Cancer Ther. 5 (2006), 2634–2643.
40. Orimo, A., Weinberg, R.A., Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5 (2006), 1597–1601.
41. Pixley, F.J., Stanley, E.R., CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 14 (2004), 628–638.
42. Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., Olson, O.C., Quick, M.L., Huse, J.T., Teijeiro, V., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19 (2013), 1264–1272.
43. Ramachandran, I.R., Condamine, T., Lin, C., Herlihy, S.E., Garfall, A., Vogl, D.T., Gabrilovich, D.I., Nefedova, Y., Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. Cancer Lett. 371 (2016), 117–124.
44. Ries, C.H., Cannarile, M.A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L.P., Feuerhake, F., Klaman, I., et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25 (2014), 846–859.
45. Ries, C.H., Hoves, S., Cannarile, M.A., Ruttinger, D., CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Curr. Opin. Pharmacol. 23 (2015), 45–51.
46. Sasse, S., Alram, M., Muller, H., Smardova, L., Metzner, B., Doehner, H., Fischer, T., Niederwieser, D.W., Schmitz, N., Schafer-Eckart, K., et al. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leuk. Lymphoma 57 (2016), 1067–1073.
47. Sionov, R.V., Assi, S., Gershkovitz, M., Sagiv, J.Y., Polyansky, L., Mishalian, I., Fridlender, Z.G., Granot, Z., Isolation and characterization of neutrophils with anti-tumor properties. J. Vis. Exp., 2015, e52933.
48. Sluijter, M., van der Sluis, T.C., van der Velden, P.A., Versluis, M., West, B.L., van der Burg, S.H., van Hall, T., Inhibition of CSF-1R supports T-cell mediated melanoma therapy. PLoS One, 9, 2014, e104230.
49. Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., Bronte, V., Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. N.Y. Acad. Sci. 1319 (2014), 47–65.
50. Strachan, D.C., Ruffell, B., Oei, Y., Bissell, M.J., Coussens, L.M., Pryer, N., Daniel, D., CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology, 2, 2013, e26968.
51. Szkandera, J., Absenger, G., Liegl-Atzwanger, B., Pichler, M., Stotz, M., Samonigg, H., Glehr, M., Zacherl, M., Stojakovic, T., Gerger, A., Leithner, A., Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br. J. Cancer 108 (2013), 1677–1683.
52. Talmadge, J.E., Gabrilovich, D.I., History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13 (2013), 739–752.
53. Tap, W.D., Wainberg, Z.A., Anthony, S.P., Ibrahim, P.N., Zhang, C., Healey, J.H., Chmielowski, B., Staddon, A.P., Cohn, A.L., Shapiro, G.I., et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N. Engl. J. Med. 373 (2015), 428–437.
54. Vetsika, E.-K., Koinis, F., Gioulbasani, M., Aggouraki, D., Koutoulaki, A., Skalidaki, E., Mavroudis, D., Georgoulias, V., Kotsakis, A., A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J. Immunol. Res., 2014, 2014, 659294.
55. Wang, L.C., Lo, A., Scholler, J., Sun, J., Majumdar, R.S., Kapoor, V., Antzis, M., Cotner, C.E., Johnson, L.A., Durham, A.C., et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2 (2014), 154–166.
56. Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A.J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol. Res. 4 (2016), 345–353.
57. Xu, J., Escamilla, J., Mok, S., David, J., Priceman, S., West, B., Bollag, G., McBride, W., Wu, L., CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 73 (2013), 2782–2794.
58. Yang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., Dang, Y., Chu, Y., Fan, J., He, R., FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 76 (2016), 4124–4135.
59. Zhang, S., Ma, X., Zhu, C., Liu, L., Wang, G., Yuan, X., The role of myeloid-derived suppressor cells in patients with solid tumors: a meta-analysis. PLoS One, 11, 2016, e0164514.
60. Zhang, Y., Ma, C., Wang, M., Hou, H., Cui, L., Jiang, C., Sun, J., Qu, X., Prognostic significance of immune cells in the tumor microenvironment and peripheral blood of gallbladder carcinoma patients. Clin. Transl. Oncol. 19 (2016), 477–488.
61. Zhu, Y., Knolhoff, B.L., Meyer, M.A., Nywening, T.M., West, B.L., Luo, J., Wang-Gillam, A., Goedegebuure, S.P., Linehan, D.C., DeNardo, D.G., CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74 (2014), 5057–5069.